Drug intelligence / Profile preview

cyclophosphamide + fludarabine + sargramostim

Development stage: Unknown
Lead developer: Partner Therapeutics
Modality: Small Molecules
Administration: Intravenous, Oral, Subcutaneous

Overview

A combination chemotherapy regimen consisting of the alkylating agent cyclophosphamide, the purine nucleoside analog fludarabine, and the growth factor sargramostim (GM-CSF). This combination is used primarily in the treatment of hematologic malignancies, particularly chronic lymphocytic leukemia (CLL) and low-grade non-Hodgkin's lymphoma (NHL). Cyclophosphamide damages DNA of cancer cells, fludarabine interferes with DNA synthesis, and sargramostim stimulates white blood cell production to help prevent infection during chemotherapy.

Targets

CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)DNA

Beyond the preview

Go deeper on cyclophosphamide + fludarabine + sargramostim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cyclophosphamide + fludarabine + sargramostim.

Explore the full profile